New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
19:48 EDTLLY, TEVAEli Lilly patent for Alimta held up by court through 2022
Eli Lilly (LLY) announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding the vitamin dosage regimen patent for Alimta. In the case of Eli Lilly vs. Teva (TEVA) the court ruled the vitamin dosage regimen patent is valid and enforceable. The patent provides intellectual property protection for Alimta until 2022. Alimta's compound patent remains in force through early 2017.
News For LLY;TEVA From The Last 14 Days
Check below for free stories on LLY;TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 31, 2014
08:32 EDTTEVATeva says delivering on cost reduction program, sees $2B in savings by 2017
Subscribe for More Information
07:04 EDTTEVATeva raises FY14 EPS view to $4.90-$5.10 in exclusive Copaxone scenario
Subscribe for More Information
07:03 EDTTEVATeva reports Q2 EPS $1.23, consensus $1.22
Subscribe for More Information
06:10 EDTLLYEli Lilly downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Eli Lilly (LLY) to Neutral saying Alimta upside and the company's pipeline is largely priced into shares at current levels. Citi raised its price target for Lilly shares to $66 from $60 and said it prefers Bristol-Myers (BMY) and Pfizer (PFE) in the U.S.
July 29, 2014
08:50 EDTLLYHarris & Harris invests in Accelerator Corporation
Subscribe for More Information
July 25, 2014
07:14 EDTTEVATeva August weekly volatility elevated into Q2 and outlook
Teva August weekly call option implied volatility is at 34, August is at 25, September and January is at 22; compared to its 26-week average of 27 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 31.
July 24, 2014
09:26 EDTLLYEli Lilly CEO says company on track to meet FY goals
Subscribe for More Information
07:27 EDTTEVASome of Teva's biggest investors to vote against re-electing directors, WSJ says
Subscribe for More Information
06:45 EDTTEVATeva price target raised to $70 from $65 at Barclays
Subscribe for More Information
06:38 EDTLLYEli Lilly says Q2 revenue declined 17% due to patent expirations
Subscribe for More Information
06:37 EDTLLYEli Lilly sees research, development charge of $45M in Q3
In July, Eli Lilly announced a co-discovery and co-development collaboration with Immunocore to research and potentially develop novel T cell-based cancer therapies. As a result of the transaction, the company expects to incur an in-process research and development charge of $45M, or approximately 3c per share Q3. In Q2, the company recognized asset impairment, restructuring and other special charges of $63.5M, primarily related to costs associated with the decision to close a packaging and distribution facility in Germany.
06:35 EDTLLYEli Lilly reaffirms 2014 EPS outlook $2.72-$2.80, consensus $2.78
Subscribe for More Information
06:33 EDTLLYEli Lilly reports Q2 EPS 68c, consensus 65c
Reports Q2 revenue $4.94B, consensus $4.9B.
July 23, 2014
15:30 EDTLLYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
14:06 EDTLLYEarnings Preview: Lilly counts on newer drugs to drive revenue
Subscribe for More Information
10:02 EDTTEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTTEVADeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use